Cor Vasa 2026, 68(3):286-294

Midterm Evaluation of Results After Meril Myval Transcatheter Aortic Valve Replacement: One-Year Clinical and Echocardiographic Findings from the MERAM Registry

Yakup Alsancak, Ahmet Seyfettin Gürbüz, Hasan Kan, Muhammed Fatih Kaleli, Mustafa Celik, Sefa Tatar, Ahmet Lütfü Sertdemir, Enes Elvin Gül, Mehmet Akif Düzenli
Department of Cardiology, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey

Background: The Myval™ transcatheter heart valve is a next-generation, balloon-expandable transcatheter aortic valve replacement (TAVR) system designed for precise implantation and improved clinical outcomes. This study presents our experience with the first 101 cases (2022-2024), evaluating 30-day and one-year outcomes.

Aim: To assess the safety and efficacy of the Myval™ TAVR system in patients with degenerative aortic stenosis (AS).

Materials and methods: This single-center observational study included 101 consecutive patients with AS who underwent TAVR with Myval™ between January 2022 and January 2024. The mean age was 76.9 ± 7.0 years, and 60 (59.4%) were females. The mean EuroSCORE II and STS score were 4.85 ± 3.91 and 5.84 ± 4.82, respectively. All procedures were performed via the femoral approach. Patients underwent echocardiographic follow-up at one month and clinical follow-up at one year.

Results: The procedural success rate was 100% (101/101). The mean hospital stay was 5.8 ± 2.4 days. Within 30 days, stroke occurred in 1.98% (2/101) of cases, and 15.8% (16/101) required new permanent pacemaker implantation. At discharge, mild aortic regurgitation was observed in 10.9% (11/101) and moderate regurgitation in 1.9% (2/101), with no significant paravalvular leak. Intrahospital mortality was 2% (2/101), while one-year all-cause mortality was 6% (6/101).

Conclusion: TAVR with the Myval™ transcatheter heart valve system demonstrates excellent 30-day and one-year outcomes regarding survival, procedural success, and valve-related adverse events, supporting its safety and efficacy in treating degenerative AS.

Keywords: Aortic valve disease, Balloon-expandable valve, Degenerative aortic stenosis, Myval™ transcatheter heart valve, Transcatheter aortic valve replacement

Received: November 4, 2025; Revised: November 5, 2025; Accepted: December 18, 2025; Prepublished online: June 2, 2012; Published: July 1, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Alsancak Y, Seyfettin Gürbüz A, Kan H, Kaleli MF, Celik M, Tatar S, et al.. Midterm Evaluation of Results After Meril Myval Transcatheter Aortic Valve Replacement: One-Year Clinical and Echocardiographic Findings from the MERAM Registry. Cor Vasa. 2026;68(3):286-294.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Willner N, Prosperi-Porta G, Lau L, et al. Aortic Stenosis Progression: A Systematic Review and Meta-Analysis. JACC Cardiovasc Imaging 2023;16:314-328.
    2. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2021;77:e25-e197.
    3. Vahanian A, Beyersdorf F, Praz F, et al. ESC/EACTS Scientific Document Group , ESC National Cardiac Societies , 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2022;43:561-632.
    4. Lee G, Chikwe J, Milojevic M, et al. ESC/EACTS vs. ACC/AHA guidelines for the management of severe aortic stenosis. Eur Heart J 2023;44:796-812.
    5. Sharma T, Krishnan AM, Lahoud R, et al. National Trends in TAVR and SAVR for Patients With Severe Isolated Aortic Stenosis. J Am Coll Cardiol 2022;80:2054-2056.
    6. Thiele H, Kurz T, Feistritzer HJ, et al. Comparison of newer generation self-expandable vs. balloon-expandable valves in transcatheter aortic valve implantation: the randomized SOLVE-TAVI trial. Eur Heart J 2020;42:1890-1899.
    7. Nieuwkerk A.C, Santos, R.B, Andraka L, et al. Balloon-Expandable versus Self-Expandable Valves in Transcatheter Aortic Valve Implantation: Complications and Outcomes from a Large International Patient Cohort. J Clin Med 2021;10: 4005.
    8. Elgendy IY, Gad MM, Mahmoud AN, et al. Meta-analysis Comparing Outcomes of Self-Expanding Versus Balloon-Expandable Valves for Transcatheter Aortic Valve Implantation. Am J Cardiol 2020;128:202-209.
    9. D'Ascenzo F, Bruno F, Baldetti L, et al. Aortic valve replacement vs. balloon-expandable and self-expandable transcatheter implantation: A network meta-analysis. Int J Cardiol 2021;15:90-98.
    10. Sharma SK, Rao RS, Chandra P, et al. First-in-human evaluation of a novel balloon-expandable transcatheter heart valve in patients with severe symptomatic native aortic stenosis: the MyVal-1 study. EuroIntervention 2020;16:421-429.
    11. Sengottuvelu G, Kumar V, Seth A. The Myval Transcatheter Heart Valve System for the Treatment of Severe Aortic Stenosis - Current Evidence and Future Directions. Heart Int 2020;14:86-91. Go to original source...
    12. Amber KA, Ammar JM. Early Outcomes of Transcatheter Aortic Valve Implantation with Next-Generation Balloon-Expandable Myval Transcatheter Heart Valve: Single-Center Experience from Iraq. Journal of the Saudi Heart Association 2024;36 (1):9.
    13. Kilic T, Ielasi A, Ninios V, et al. Clinical outcomes of the Myval transcatheter heart valve system in patients with severe aortic valve stenosis: a two-year follow-up observational study. Arch Med Sci 2024;20:410-419.
    14. Sharma SK, Rao RS, Chopra M, et al. Myval Transcatheter Heart Valve System in the Treatment of Severe Symptomatic Aortic Stenosis. Future Cardiol 2021;17:73-80.
    15. Halim J, den Heijer P, van den Branden B, et al. Short-term outcome after transcatheter aortic valve replacement with a novel balloon-expandable valve. Neth Heart J 2023;31:500-505.
    16. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 2002;106:3006-3008.
    17. Cribier A. Development of transcatheter aortic valve implantation (TAVI): a 20-year odyssey. Arch Cardiovasc Dis 2012;105:146-152.
    18. Kawashima H, Soliman O, Wang R, et al. Rationale and design of a randomized clinical trial comparing safety and efficacy of myval transcatheter heart valve versus contemporary transcatheter heart valves in patients with severe symptomatic aortic valve stenosis: The LANDMARK trial. Am Heart J 2021;232:23-38. Go to original source...
    19. Terkelsen CJ, Thim T, Freeman P, et al. Randomized comparison of TAVI valves: The Compare-TAVI trial. Am Heart J 2024;274:84-94. Go to original source...
    20. Blanco F, Chowdhury D, De Brahi J, et al. Initial experience with the Myval ballon-expandable valve in Argentina. Revista Argentina de Cardioangiología Intervencionista 2024;15:51-57.
    21. Arslan U, Erdoğan G, Uçar M, et al. First experiences with the balloon-expandable Myval® transcatheter aortic valve from Turkey. Anatol J Cardiol 2020;24:361-363.
    22. Magyari B, Kittka B, Goják I, et al. Single center experience with the balloon-expandable Myval transcatheter aortic valve system with the first 100 patients: 30-day and 1-year follow-up. Catheter Cardiovasc Interv 2023;102:1317-1330. Go to original source...
    23. Hasabo E, Abo Ali A, Hemmeda L, et al. 30-day and one-year outcomes of patients with severe aortic stenosis after TAVI using Myval: A Meta-analysis. Circulation 2024;150(Suppl 1). https://doi.org/10.1161/circ.150.suppl_1.4146472 Go to original source...
    24. Leclercq F, Robert P, Akodad M, et al.Prior Balloon Valvuloplasty Versus Direct Transcatheter Aortic Valve Replacement: Results From the DIRECTAVI Trial. JACC Cardiovasc Interv 2020;13:594-602. Go to original source...
    25. Durand E, Avinée G, Gillibert A, et al. Analysis of length of stay after transfemoral transcatheter aortic valve replacement: results from the FRANCE TAVI registry. Clin Res Cardiol 2021;110:40-49. Go to original source...
    26. Takeji Y, Taniguchi T, Morimoto T, et al. In-hospital outcomes after SAVR or TAVI in patients with severe aortic stenosis. Cardiovasc Interv Ther 2024;39:65-73. Go to original source...
    27. Cheng D. Local or general anesthesia for TAVI surgery? An updated systematic review and meta-analysis. Eur Heart J 2021;42(Suppl 1)ehab724.1670. doi: 10.1093/eurheartj/ehab724.1670. Go to original source...
    28. Maas EH, Pieters BM, Van de Velde M, et al. General or Local Anesthesia for TAVI? A Systematic Review of the Literature and Meta-Analysis. Curr Pharm Des 2016;22:1868-1878. Go to original source...
    29. Poels T, Houthuizen P, Van Garsse L, et al. Transcatheter Aortic Valve Implantation-Induced Left Bundle Branch Block: Causes and Consequences. J Cardiovasc Trans Res 2014;7:395-405. Go to original source...
    30. Massoullié G, Ploux S, Souteyrand G, et al. Incidence and management of atrioventricular conduction disorders in new-onset left bundle branch block after TAVI: A prospective multicenter study. Heart Rhythm 2023;20:699-706.
    31. Massoullié G, Bordachar P, Irles D, et al. Prognosis assessment of persistent left bundle branch block after TAVI by an electrophysiological and remote monitoring risk-adapted algorithm: rationale and design of the multicentre LBBB-TAVI Study. BMJ Open 2016;6:e010485.
    32. Eschalier R, Massoullié G, Nahli Y, et al. New-Onset Left Bundle Branch Block After TAVI has a Deleterious Impact on Left Ventricular Systolic Function. Can J Cardiol 2019;35:1386-1393.
    33. Megaly M, Abraham B, Abdelsalam M, et al. Short- and Long-Term Outcomes in Patients With New-Onset Persistent Left Bundle Branch Block After Transcatheter Aortic Valve Replacement. Cardiovasc Revasc Med 2020;21:1299-1304. Go to original source...
    34. Ando T, Takagi H. The Prognostic Impact of New-Onset Persistent Left Bundle Branch Block Following Transcatheter Aortic Valve Implantation: A Meta-analysis. Clin Cardiol 2016;39:544-550. Go to original source...
    35. Postolache A, Sperlongano S, Lancellotti P. TAVI after More Than 20 Years. J Clin Med 2023;12:5645.
    36. Guetta V, Goldenberg G, Segev A, et al. Predictors and course of high-degree atrioventricular block after transcatheter aortic valve implantation using the CoreValve Revalving System. Am J Cardiol 2011;108:1600-1605.
    37. Testa L, Criscione E, Popolo Rubbio A, et al. Safety and performance parameters of the Myval transcatheter aortic valve bioprosthesis: The SAPPHIRE prospective registry. Cardiovasc Revasc Med 2023;55:22-27. Go to original source...
    38. Meril Life Sciences. Myval THV: Designed for Precision in Outcomes. 2022. Online. Available from: www.merillife.com/medical-devices/vascular-intervention/heart-valves/tavr/myval [cited 2025-03-04].

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content